Written by: Center for Care Innovations

In this PHASE Wireside Chat — our webinar series by clinicians for clinicians — Dr. Lisa Gilliam of Kaiser Permanente joined us to give us an update on the current standards of care and medical treatments for patients with diabetes.

The prevalence of diabetes and associated costs have exploded over the last 2 decades. Prevention is preferable, but a solid population health approach to diabetes has helped Kaiser Permanente Northern California effectively treat patients with diabetes.

Who Should watch this Webinar?

Anyone interested in developing a deeper understanding of the medications involved in caring for patients with diabetes. This webinar, geared towards clinicians and QI leads, covers current guidelines and presents sample patient cases for diabetes medication treatments.

Our takeaways:

  1. The 7% A1c glycemic target is still used as the general threshold, with the caveat that glycemic goals should be individualized based on patient considerations (such as the duration of diabetes, age/life expectancy, comorbidities, known CVD complications, hypoglycemia unawareness and others.)
  2. KP uses a dual therapy approach. Metformin, Sulfonylureas, and Basal Insulins remain first line drugs considering their advantages, efficacy, and cost. For high risk patients, factor in second line agents and patient considerations to make treatment decisions.
  3. To achieve their high level of DM control, KP combines these medication algorithms with population health tools, such as dedicated diabetes panel managers called Accountable Population Managers (APMs), preventative status/reminder dashboards (PROMPT at KP), and regular reporting on related measures.

Download Slides

Download Q&As

About the Speaker

Lisa Gilliam, MD, PhD
Clinical Leader, Kaiser Northern California Diabetes Program
South San Francisco Endocrinology Sub-Chief, the Permanente Medical Group

Dr. Gilliam completed her MD/PHD at Duke University, followed by a residency in Internal Medicine and a fellowship in endocrinology, both at the University of Washington. She then spent three years as part of the diabetes and endocrinology faculty at Seattle Children’s and became the regional expert in the treatment of monogenic forms of diabetes. In 2012, she joined the Endocrinology team at Kaiser Permanente in South San Francisco and now serves as the clinical leader for the Kaiser Permanente Northern California’s Diabetes Program.



Find this useful or interesting? We’re constantly sharing stuff like this. Sign up to receive our newsletter to stay in the loop.